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Objectives The aim of this meta-analysis was to evaluate the effects of additional trimetazidine (TMZ) treatment on pa-
tients with chronic heart failure (CHF).
Background Conflicting results currently exist on the clinical use of TMZ in CHF patients.
Methods PubMed, MEDLINE, EMBASE, and EBM Reviews databases were searched through November 2010 for random-
ized controlled trials (RCTs) assessing TMZ treatment in CHF patients. Data concerning the study design, patient
characteristics, and outcomes were extracted. Risk ratio (RR) and weighted mean differences (WMD) were cal-
culated using fixed or random effects models.
Results Sixteen RCTs involving 884 CHF patients were included. Hospitalization for cardiac causes (RR: 0.43, p  0.03),
but not all-cause mortality (RR: 0.47, p  0.27), was reduced by TMZ treatment. Moreover, TMZ therapy was
associated not only with the increase of left ventricular ejection fraction (WMD: 6.46%, p  0.0001) and total
exercise time (WMD: 63.75 seconds, p  0.0001), but also with the decrease of New York Heart Association func-
tional class (WMD: 0.57, p  0.0003), left ventricular end-systolic diameter (WMD: 6.67 mm, p  0.0001), left
ventricular end-diastolic diameter (WMD: 6.05 mm, p  0.0001), and B-type natriuretic peptide (WMD: 203.40
pg/ml, p  0.0002).
Conclusions Additional use of TMZ in CHF patients may decrease hospitalization for cardiac causes, improve clinical symp-
toms and cardiac function, and simultaneously ameliorate left ventricular remodeling. (J Am Coll Cardiol
2012;59:913–22) © 2012 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2011.11.027Despite therapeutic advances, chronic heart failure (CHF)
remains a major cause of mortality in the worldwide.
Evidence suggests that the alterations in energy metabolism,
such as high rates of fatty acid oxidation, may lead to
abnormal function of the failing heart (1,2).
Trimetazidine (1-[2,3,4-trimethoxybenzyl] piperazine
dihydrochloride, TMZ), which shifts energy production
from fatty acid oxidation to glucose oxidation (3), is
effective in stable angina pectoris (4). Studies have shown
that TMZ exerted cardioprotective effects by reducing
oxidative damage, inhibiting inflammation and apoptosis,
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011, accepted November 11, 2011.and improving endothelial function (5–7). TMZ was, there-
fore, considered a promising candidate for the treatment of
CHF.
This meta-analysis of randomized controlled trials (RCTs)
was performed to estimate the effects of TMZ treatment on
CHF patients.
Methods
Search strategy and selection criteria. We performed an
electronic literature search of PubMed, MEDLINE,
EMBASE, and EBM Reviews databases through Novem-
ber 2010, using the terms “trimetazidine,” “Vastarel,” “Idap-
tan,” “heart failure,” “cardiac dysfunction,” “cardiac insuffi-
ciency,” “cardiac inadequacy,” “cardiomyopathy,” and
“ventricular dysfunction.” The references of the studies were
also searched for relevant titles.
RCTs in which CHF patients were assigned to TMZ or
placebo were included. Exclusion criteria were: 1) treatment
interval 4 weeks; 2) cross-over trials without washout
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text for quality assessment and
data extraction.
Data extraction and quality as-
sessment. Two investigators in-
dependently reviewed all poten-
tially eligible studies and collected
data on patient and study charac-
teristics. Quality assessments were
evaluated with Jadad quality scale.
Data synthesis and analysis.
Dichotomous data were analyzed
using risk ratio (RR) with 95%
confidence intervals, whereas con-
tinuous variables (change from
baseline to follow-up) were ana-
lyzed using weighted mean differ-
ences (WMD) or standardized
mean differences (SMD). Pooled
analyses were calculated using
fixed-effect models, whereas
random-effect models were applied in case of significant
heterogeneity across studies. When no events were ob-
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CHF  chronic heart failure
hsCRP  high-sensitivity
C-reactive protein
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
RCT  randomized
controlled trial
RR  risk ratio
SMD  standardized mean
differences
TMZ  trimetazidine
WMD  weighted mean
differencesFigure 1 Search Flow Diagram for Studies Included in the Meta-Anaserved, 0.5 was added to both arms of the trial. Statistical
heterogeneity were measured using the I2 statistic. Meta-
egression analyses were conducted to estimate the extent to
hich other covariates might have influenced the treatment
ffects. Sensitivity analyses (exclusion of 1 study at a time)
ere performed to determine the stability of the overall
reatment effects. Additionally, publication bias was assessed
sing the Begg adjusted rank correlation test and Egger
egression asymmetry test. All p values were 2-tailed, and
he statistical significance was set at 0.05. Statistical analyses
ere performed using RevMan 5.0 (The Cochrane Collab-
ration, Copenhagen, Denmark), STATA software 10.0
StataCorp, College Station, Texas), and nlme package in R
anguage 2.12.1.
esults
ligible studies. The flow of selecting studies for the
eta-analysis is shown in Figure 1. Briefly, of the initial 499
its, 84 articles were retrieved for detailed evaluation, and
6 RCTs (8–23) satisfying the inclusion criteria were finally
nalyzed.lysis
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March 6, 2012:913–22 A Meta-Analysis of Trimetazidine for CHFCharacteristics of 16 Clinical Trials Included in the Meta-AnalysisTable 1 Characteristics of 16 Clinical Trials Included in the Meta-Analysis
First Author, Year (Ref. #)
Individuals
Randomized, n
Age
(Mean, yrs)
Female
(%)
Etiology
(Ischemic, %)
DM
(%)
NYHA
Functional ClassTMZ Control TMZ Control TMZ Control
Belardinelli et al., 2001 (8) 19 19 50 54 21 16 100 NA II–III
Belardinelli et al., 2007 (9) 27 24 51 52 35 23 100 33 NA
Belardinelli et al., 2008 (10) 19 16 54 54 16 13 100 100 NA
Brottier et al., 1990 (11) 9 11 57 62 5 (overall)* 100 NA III–IV
Cera et al., 2010 (12) 17 13 65 70 12 15 60 37 I–III
Di Napoli et al., 2005 (13) 30 31 67 69 43 42 100 20 II–IV
Di Napoli et al., 2007 (14) 25 25 64 63 40 28 100 24 II–IV
El-Kady et al., 2005 (15) 100 100 53 53 14 22 100 34 NA
Fragasso et al., 2006 (16) 34 31 64 66 11 7 54 7 II–IV
Gunes et al., 2009 (17) 51 36 59 57 27 42 66 29 II–III
Rosano et al., 2003 (18) 16 16 66 65 31 19 100 100 NA
Sisakian et al., 2007 (19) 42 40 64 66 12 17 100 0 II–III
Thrainsdottir et al., 2004 (20) 10 10 67 66 10 20 100 100 II–III
Tuunanen et al., 2008 (21) 12 7 59 57 17 29 0 0 2.2 0.3†
Vitale et al., 2004 (22) 23 24 77 78 22 8 100 26 I–III
Zemljic et al., 2010 (23) 25 22 65 66 18 25 100 NA II–III
LVEF
(Mean, %)
TMZ
(Dose, mg/Day)
Follow-Up
(Mean) Endpoints
Belardinelli et al., 2001 (8) 33 60 2 months Adverse events, contractile response to dobutamine,
left ventricular systolic function and functional capacity
Belardinelli et al., 2007 (9) 33 60 4 weeks Adverse events, endothelium-dependent relaxation, functional
capacity and indices of cardiovascular efficiency
Belardinelli et al., 2008 (10) 38 60 3 months Adverse events, left ventricular function and structure,
blood biochemical indices
Brottier et al., 1990 (11) 25 60 6 months Adverse events, left ventricular function and structure
Cera et al., 2010 (12) 36 60 6 months Adverse events, left ventricular function, NYHA functional class,
electrophysiological indices
Di Napoli et al., 2005 (13) 31 60 18 months Adverse events, Left ventricular function and structure,
NYHA functional class, CRP
Di Napoli et al., 2007 (14) 29 60 6 months Adverse events, left ventricular function, NYHA functional class,
6-minute walk, BNP, cTnT
El-Kady et al., 2005 (15) 36 60 23 months Adverse events, anginal attacks/weekly, left ventricular function
and structure, exercise capacity
Fragasso et al., 2006 (16) 35 60 13 months Adverse events, left ventricular function and structure,
NYHA functional class, QOL, heart rate, blood pressure, BNP
Gunes et al., 2009 (17) 32 60 3 months Left ventricular function and structure, NYHA functional class,
heart rate, blood pressure
Rosano et al., 2003 (18) 33 60 6 months Left ventricular function and structure, heart rate, blood pressure
Sisakian et al., 2007 (19) 33 70§ 3 months Adverse events, left ventricular function and structure,
NYHA functional class, 6-minute walk
Thrainsdottir et al., 2004 (20) 31 60 4 weeks Adverse events, left ventricular function, exercise capacity
Tuunanen et al., 2008 (21) 34 70§ 3 months Adverse events, left ventricular function and structure, heart rate,
blood pressure, myocardial metabolism
Vitale et al., 2004 (22) 29 60 6 months Adverse events, left ventricular function and structure,
NYHA functional class, anginal attacks/week, QOL
Zemljic et al., 2010 (23) 55‡ 70§ 1 month Electrophysiological index (corrected QT interval)
*Percentage in all included patients; †Mean NYHA functional class in all included patients; ‡LVEF in all included patients were 55%; §Modified form of TMZ.
BNP brain natriuretic peptide; CRP C-reactive protein; cTnT cardiac troponin T; DM diabetes mellitus; LVEF left ventricular ejection fraction; NYHA New York Heart Association; QOL quality
f Life; TMZ  trimetazidine.
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Table 1. Table 1 summarizes the characteristics of the
included trials. Specifically, 459 patients were assigned to
TMZ, whereas 425 subjects were assigned to control. All
studies have enrolled patients with reduced left ventricular
ejection fraction (LVEF).
All-cause mortality and hospitalization for cardiac causes.
On the whole, TMZ treatment was well tolerated in CHF
patients. The results showed all-cause mortality in the
TMZ group was not lower than control (RR: 0.47, p 
0.27). Nevertheless, 7 of 80 patients with TMZ treatment
needed hospitalization for cardiac causes, which was signif-
icantly 17 of 76 patients assigned to control (RR: 0.43,
p  0.03) (Fig. 2). Sensitivity analyses suggested that this
beneficial effect was concealed when the study by Fragasso
et al. (16) (p  0.08) or by Vitale et al. (22) (p  0.07) was
omitted.
Left ventricular structure and function. The results indi-
cated that additional TMZ therapy was superior to standard
therapy in terms of LVEF improvement (WMD: 6.46%,
p  0.0001). Furthermore, TMZ therapy was similarly
found to reduce left ventricular end-systolic diameter
(WMD: 6.67 mm, p  0.0001), left ventricular end-
diastolic diameter (WMD: 6.05 mm, p  0.0001), and
left ventricular end-systolic volume (SMD: 0.61, p 
0.02). Additionally, TMZ therapy tended to decrease left
ventricular end-diastolic volume (SMD: 0.38, p  0.10)
(Fig. 3).
Sensitivity analyses confirmed in direction and magnitude
of statistical significance the results regarding LVEF. Ac-
cording to the results of meta-regression analyses, no
statistically significant association was found between: the
Figure 2 Forest Plots for All-Cause Mortality and Hospitalizatio
(A) All-cause mortality; (B) hospitalization for cardiac causes. CI  confidence intebenefits of TMZ therapy and year of publication, age of
patients, etiology of CHF, baseline LVEF, baseline New
York Heart Association (NYHA) functional class, and
follow-up duration. Nevertheless, we found a statistically
significant association between patients’ sex and LVEF
improvement (p  0.03) (Fig. 4). Subgroup analyses
showed the original form of TMZ significantly increased
LVEF (p  0.0001), whereas the modified form did not
(Table 2). Moreover, the difference in LVEF improvement
was not shown on etiology, as indicated by indirect com-
parison (p 0.99). No publication bias was found, as shown
by Egger’s test (p  0.16) and Begg’s test (p  0.83)
(Online Fig. 1).
Functional capacity. Benefits of TMZ treatment were
shown on both NYHA functional class (WMD: 0.57,
p  0.0003) and total exercise time (WMD: 63.75
seconds, p  0.0001) (Figs. 5A and 5B). Subgroup
analyses indicated that ischemic CHF patients with
baseline LVEF 30% were more likely to get such
benefits from TMZ treatment (Table 2).
Blood pressure and heart rate. Resting heart rate in the
TMZ group was slightly lower than that of the control group
(WMD: 2.62 beats/min, p  0.04), whereas no significant
ifferences were observed in resting systolic blood pressure
WMD: 0.94 mm Hg, p  0.42) or resting diastolic blood
ressure (WMD:1.86 mm Hg, p 0.27) (Figs. 5C to 5E).
erum markers. B-type natriuretic peptide (BNP) level was
ignificantly down-regulated by TMZ treatment (WMD:
203.40 pg/ml, p 0.0002), whereas high-sensitivity C-reactive
rotein (hsCRP) level was not (WMD: 2.45 mg/l, p  0.10)
Figs. 6A and 6B).
Cardiac Causes
M-H  Mantel-Haenszel; RR  relative risk; TMZ  trimetazidine.n for
rvals;
917JACC Vol. 59, No. 10, 2012 Zhang et al.
March 6, 2012:913–22 A Meta-Analysis of Trimetazidine for CHFFigure 3 Forest Plots for Left Ventricular Structure and Function
(A) Left ventricular ejection fraction; (B) left ventricular end-systolic diameter; (C) left ventricular end-diastolic diameter;
(D) left ventricular end-systolic volume; (E) left ventricular end-diastolic volume. IV  inverse variance; other abbreviations as in Figure 2.
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therapy tended to be, albeit nonsignificantly, associated
with corrected QT interval shortening (WMD: 31.32
ms, p  0.07).
Discussion
The main findings of this meta-analysis are that although
the additional use of TMZ failed to reduce all-cause
mortality in CHF patients, the beneficial effects have
been demonstrated by the increase of LVEF and total
exercise time, and by the decrease of hospitalization for
cardiac causes, NYHA class and of left ventricular end-
systolic diameter, left ventricular end-diastolic diameter,
left ventricular end-systolic volume, and serum BNP
level. Moreover, as illustrated by the unchanged resting
blood pressure and an average decrease of a mere 2.6
beats/min in resting heart rate, our study indicated that
the aforementioned beneficial effects may be hemody-
namically neutral.
The well-established anti-ischemic effects of TMZ are
thought to be mediated by reducing fatty acid
-oxidation and increasing glucose oxidation, resulting in
igher ATP production (3,24). Combining these findings
ith the “energy starvation” hypothesis, which suggests
hat inadequate ATP supply underlies the contractile
ysfunction presenting in heart failure (25), it seems
lausible that TMZ improves energy metabolism in
ardiomyocytes, which may finally translate into mechan-
cal efficiency and contribute to the improvement of
ardiac function and clinical symptoms. Besides, it is
oteworthy that TMZ exerts cardioprotective effects by
estoring phosphorylation processes, inhibiting inflam-
Figure 4 Meta-Regression Between
Patient Sex and LVEF Improvement
LVEF  left ventricular ejection fraction; WMD  weighted mean differences.atory response, oxidative damage, and apoptosis, as wells by improving endothelial function and coronary mi-
rocirculation (5-7,26,27), which may account for the
melioration of left ventricular remodeling. Furthermore,
t seems reasonable that the BNP level could be down-
egulated by TMZ treatment, considering that the BNP
evel is negatively related to the alteration of cardiac
tructure and function (28).
TMZ treatment may play beneficial roles, not only in
ardiac structural remodeling, but in electrical remodel-
ng (29). Moreover, inflammatory mediators are involved
n the pathogenesis of CHF (e.g., hsCRP), whereas the
nti-inflammatory effects of TMZ have been observed
6,30). Unexpectedly, we failed to show the beneficial
ffects of TMZ either on corrected QT interval or on
sCRP, which may be due to the insufficiently powered
tudies included.
Subgroup estimation indicated that clinical symptoms
nd left ventricular structure in ischemic CHF patients
ere more likely to be ameliorated with TMZ treatment,
evertheless, such superiority may not totally deny the
tility of TMZ in nonischemic CHF, with respect to
VEF improvement. Furthermore, modified TMZ may
ield less benefits than the original form in LVEF
nhancement, which may be associated with the differ-
nce in pharmacokinetics (31). Additionally, it was
hown that female patients were more likely to get
enefits from TMZ therapy regarding LVEF, suggesting
hat the difference in the proportion of female patients
ight be an origin of the interstudy discrepancy.
tudy limitations. Drawbacks pertinent to this meta-
nalysis were the differences in characteristics among in-
luded studies, encompassing patients’ age, follow-up dura-
ion, and so on. Moreover, it is worth noticing that only 884
atients were involved in the 16 RCTs, which justifies the
erformance of more large-scale RCTs for evaluating the
mpact of TMZ treatment on CHF patients.
onclusions
he additional use of TMZ in CHF patients may exert
eneficial effects, not only in ameliorating clinical symptoms
nd left ventricular structure and function, but in reducing
ospitalization for cardiac causes, indicating that it may be
n additional therapeutic agent for CHF.
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Subgroup Estimation of the Effects of TMZ Therapy on Patients With CHFTable 2 Subgroup Estimation of the Effects of TMZ Therapy on Patients With CHF
LVEF NYHA Functional Class LVEDV
Subgroup Studies/Patients, n/N WMD [95% CI] p Value Studies/Patients, n/N WMD [95% CI] p Value Studies/Patients, n/N SMD [95% CI] p Value
Age, yrs
65 7/319 6.72 [4.76 to 8.69] 0.0001 5/268 0.70 [1.09 to0.30] 0.0006 3/181 0.79 [1.85 to 0.28] 0.15
65 7/400 6.07 [4.39 to 7.76] 0.0001 2/137 0.30 [0.54 to0.06] 0.01 4/194 0.11 [0.40 to 0.17] 0.44
Etiology (ischemic, 100%)
Yes 10/528 6.45 [4.92 to 7.99] 0.0001 4/233 0.62 [1.01 to0.23] 0.002 4/214 0.67 [1.45 to 0.11] 0.09
No 4/191 6.10 [2.47 to 9.73] 0.001 3/172 0.46 [1.11 to 0.20] 0.17 3/161 0.03 [0.35 to 0.28] 0.83
All pts with DM
Yes 3/85 7.11 [4.98 to 9.24] 0.0001 — — — — — —
No 9/575 7.00 [5.27 to 8.73] 0.0001 7/402 0.57 [0.88 to0.26] 0.0003 6/337 0.45 [0.97 to 0.08] 0.10
Baseline LVEF
30% 11/604 6.74 [5.28 to 8.21] 0.0001 5/308 0.62 [1.00 to0.24] 0.001 5/281 0.11 [0.34 to 0.13] 0.38
30% 3/115 5.72 [2.36 to 9.08] 0.0008 2/97 0.37 [0.78 to 0.04] 0.08 2/94 1.23 [2.99 to 0.52] 0.17
Type of TMZ
Modified form (70 mg/day) 2/101 4.57 [1.38 to 10.53] 0.13 1/82 0.48 [0.73 to0.23] 0.0002 2/101 0.22 [0.62 to 0.17] 0.27
Original form (60 mg/day) 12/618 6.74 [5.49 to 7.99] 0.0001 6/323 0.57 [0.97 to0.18] 0.005 5/274 0.49 [1.13 to 0.16] 0.14
Follow-up, months
12 3/263 9.96 [7.68 to 12.23] 0.0001 2/109 1.01 [1.38 to0.83] 0.0001 1/55 0.06 [0.59 to 0.47] 0.83
12 11/456 5.76 [4.40 to 7.12] 0.0001 5/296 0.38 [0.54 to 0.21] 0.0001 6/320 0.45 [0.99 to 0.09] 0.10
LVESV Resting HR Resting SBP
Studies/Patients, n/N SMD [95% CI] p Value Studies/Patients, n/N WMD [95% CI] p Value Studies/Patients, n/N WMD [95% CI] p Value
Age, yrs
65 3/181 0.95 [1.95 to 0.05] 0.06 2/87 2.70 [7.27 to 1.87] 0.25 2/87 1.96 [4.76 to 0.84] 0.17
65 3/144 0.24 [0.58 to 0.09] 0.15 4/189 2.58 [5.65 to 0.48] 0.10 4/189 1.05 [2.86 to 4.97] 0.60
Etiology (ischemic, 100%)
Yes 3/164 1.08 [2.08 to0.08] 0.03 3/115 5.83 [9.26 to2.41] 0.0008 3/115 1.83 [4.33 to 0.67] 0.15
No 3/161 0.17 [0.48 to 0.14] 0.29 3/161 1.35 [2.46 to 5.15] 0.49 3/161 3.45 [2.10 to 9.01] 0.22
All pts with DM
Yes — — — 1/32 6.00 [11.59 to0.41] 0.04 1/32 2.00 [4.86 to 0.86] 0.17
No 5/287 0.61 [1.24 to 0.02] 0.06 4/206 0.79 [4.04 to 2.45] 0.63 4/206 1.73 [2.20 to 5.65] 0.39
Baseline LVEF
30% 5/281 0.32 [0.56 to0.08] 0.009 6/276 2.62 [5.16 to0.07] 0.04 6/276 0.94 [3.22 to 1.34] 0.42
30% 1/44 2.24 [3.01 to1.47] 0.0001 — — — — — —
Type of TMZ
Modified form (70 mg/day) 2/101 0.40 [0.80 to0.00] 0.05 1/19 3.00 [7.89 to 13.89] 0.59 1/19 7.00 [3.05 to 17.05] 0.17
Original form (60 mg/day) 4/224 0.78 [1.59 to 0.04] 0.06 5/257 2.94 [5.56 to0.32] 0.03 5/257 1.37 [3.71 to 0.972] 0.25
Follow-up (months)
12 1/55 0.30 [0.83 to 0.24] 0.27 1/55 4.00 [3.96 to 11.96] 0.32 1/55 1.00 [15.26 to 13.26] 0.89
12 5/270 0.69 [1.34 to0.04] 0.04 5/221 3.37 [6.06 to0.69] 0.01 5/221 0.94 [3.25 to 1.37] 0.43
CHF  chronic heart failure; CI  confidence interval; HR  heart rate; LVEDV  left ventricular end-diastolic volume; LVESV  left ventricular end-systolic volume; NYHA  New York Heart Association; SBP  systolic blood pressure; SMD  standardized mean differences;
WMD  weighted mean differences; other abbreviations as in Table 1.
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A Meta-Analysis of Trimetazidine for CHF March 6, 2012:913–22Figure 5 Forest Plots for Functional Capacity, Blood Pressure, and Heart Rate
(A) New York Heart Association functional class; (B) total exercise time; (C) resting heart rate; (D) resting systolic blood pressure;
(E) resting diastolic blood pressure. Abbreviations as in Figures 2 and 3.
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